#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

Episode Summary

Executive Summary: Peter Attia frames sleep medications as tools that must be matched to the specific sleep problem—sleep pressure, circadian timing, hyperarousal, or sleep architecture—rather than used as generic sedatives. He reviews major prescription classes, emphasizing CBT-I and sleep hygiene as foundations, the limitations and risks of benzodiazepines and Z-drugs, the promise of DORAs, the circadian role of melatonin, and the nuanced role of trazodone and supplements.

Main Topics: Framework for diagnosing sleep problems (Priority: 5/5): Sleep issues are organized into four mechanisms: sleep pressure, circadian timing, hyperarousal, and sleep architecture. The episode argues that misdiagnosis leads to poor treatment choices. Behavioral foundations and sleep hygiene (Priority: 5/5): Good sleep starts with aligning light exposure, wake times, meals, exercise, caffeine, and environment to biology. Medications are framed as secondary tools, not the base of treatment. Medical causes of poor sleep (Priority: 4/5): Before medications, the episode highlights common medical contributors such as restless leg syndrome, obstructive sleep apnea, and mood/anxiety disorders that can mimic or worsen insomnia. Comparing major sleep medication classes (Priority: 5/5): Benzodiazepines, Z-drugs, DORAs, melatonin/melatonin agonists, trazodone, and antihistamines are compared by mechanism, sleep effects, duration, and adverse effects. DORAs and sleep architecture/neuroprotection (Priority: 5/5): Dual orexin receptor antagonists are presented as the most promising newer class because they reduce wakefulness rather than forcing sedation and may preserve sleep architecture; early evidence suggests possible Alzheimer’s-relevant benefits. Supplements and quality control (Priority: 3/5): Melatonin, glycine, magnesium, ashwagandha, and phosphatidylserine are discussed, with emphasis that supplement quality is variable and evidence is mixed or limited.

Key Arguments: Sleep medications should be selected based on the underlying sleep mechanism, not used as a one-size-fits-all solution. Behavioral interventions and circadian alignment are the foundation of good sleep; drugs are best used as short-term bridges or targeted tools. Hyperarousal is the dominant driver of primary insomnia, which is why CBT-I is first-line. Benzodiazepines can rapidly reduce sleep latency and anxiety, but they impair sleep architecture, carry dependence risk, and can worsen cognition and balance. Z-drugs are not meaningfully safer in many real-world respects; they still affect memory, behavior, and dependence risk, and they can cause complex sleep behaviors. DORAs are distinct because they reduce wakefulness by blocking orexin signaling rather than broadly sedating the brain, and they tend to preserve sleep architecture. DORAs may be relevant to neurodegeneration because sleep supports glymphatic clearance of beta-amyloid and tau; however, human evidence is still early and insufficient for off-label prevention claims. Melatonin is primarily a circadian timing signal, not a sedative, and works best for jet lag, shift work, and circadian misalignment. Trazodone is often a practical sleep aid because it can increase total sleep time and slow-wave sleep with a relatively favorable tolerability profile. Antihistamines are poor long-term sleep aids because tolerance develops quickly and anticholinergic effects may contribute to cognitive harm. Supplements can be useful, but product inconsistency means label claims may not match contents; quality certification matters as much as evidence.

Data Points: U.S. adults with insufficient sleep: 36% - Share of U.S. adults failing to get the recommended seven hours of sleep per night. Adults reporting difficulty sleeping: More than 50% - Broad self-reported sleep difficulty in the U.S. Adults meeting insomnia criteria: Over 22% - Estimated prevalence of diagnosable insomnia. Adult restless leg syndrome prevalence: About 3% - Worldwide adult prevalence cited for restless leg syndrome. Americans diagnosed with restless leg syndrome: Up to 13% - American Academy of Sleep Medicine survey estimate. Likelihood of obstructive sleep apnea in U.S. adults: About one-third - Estimated prevalence due to obesity and population risk. OSA prevalence in males: Just over 39% - Sex-specific estimate for obstructive sleep apnea in U.S. males. OSA prevalence in females: 26% - Sex-specific estimate for obstructive sleep apnea in U.S. females. OSA severity distribution: About 50% mild, 30% moderate, nearly 20% severe - Breakdown of obstructive sleep apnea severity among cases. 12-month prevalence of anxiety and/or mood disorders: About one-third - U.S. adult prevalence mentioned for anxiety and mood disorders. Severe insomnia among mood/anxiety disorders: 25% to 45% - Share reporting severe insomnia in the previous year. Severe insomnia with comorbid mood and anxiety disorders: 42% to 63% - Higher insomnia burden when both disorder types coexist. DSM-5 insomnia duration threshold: More than 3 months and at least 3 nights per week - Diagnostic criteria described for insomnia. Benzodiazepine prescribing duration guidance: 2 to 4 weeks - Label-recommended short-term use versus real-world long-term use. Average benzodiazepine use duration: Nearly a decade - Meta-analytic estimate of actual use duration. Z-drug share of U.S. sleep-med prescriptions: Over 40% - Market share of Z-drugs among sleep medication prescriptions. Ambien share of Z-drug prescriptions: Nearly 90% - Dominant share within the Z-drug category. 2019 FDA black box warning: Complex sleep behaviors - Warning added for Z-drugs due to dangerous parasomnias and injuries. DORA half-life range: Quviviq 6-10 h; Belsomra ~12 h; DeVigo 17-19 h - Pharmacokinetic differences affecting next-day impairment. Human Belsomra trial size: 38 adults - Short 2023 trial of suvorexant in cognitively unimpaired adults. Human Belsomra amyloid reduction: ~20% decrease in CSF amyloid beta - Observed after 20 mg dosing in the small human trial. Melatonin optimal dose for sleep latency: 4 mg - Dose-response meta-analysis cited in the discussion of melatonin supplements. Melatonin supplement label variability: -80% to +500% of label claim - Measured content inconsistency in commercial products. Melatonin bioavailability range: 1% to 74% - Wide inter-individual and product-related variability. Trazodone sleepiness at antidepressant dose: ~50% - Patients at depression-treatment doses often experience daytime sleepiness. Trazodone placebo daytime sleepiness: 19% - Comparator rate in the cited depression trial. Ashwagandha meta-analysis sample: ~400 participants across 5 RCTs - Evidence base summarized for sleep effects. Ashwagandha effective dose: At least 600 mg/day - Stronger effects noted at higher doses in the meta-analysis. Ashwagandha duration threshold: At least 8 weeks - Longer treatment associated with better sleep effects.

Pivotal Quotes: "If sleep does not serve an absolutely vital function, then it is the biggest mistake the evolutionary process has ever made." — Peter Attia: Introduces sleep as a biological imperative and frames the importance of the topic. "Most sleep problems fall into four buckets, which actually correspond directly to the four mechanisms of insomnia." — Peter Attia: Core organizing framework for evaluating sleep complaints and matching treatments. "Melatonin is not a sleeping pill. It's a timing signal." — Peter Attia: Explains why melatonin is best for circadian misalignment rather than general insomnia.

Implications: Listeners should diagnose the cause of sleep disturbance before choosing treatment. The episode favors CBT-I and circadian/behavioral fixes first, reserves drugs for targeted use, and highlights DORAs as the most promising class for both sleep quality and possible long-term brain-health relevance.